Electro-Optical Sciences Announces Positive Top-Line Results From Landmark MelaFind(R) Pivotal Trial

Company to File PMA Application With FDA; Largest Prospective Clinical Study Ever Conducted in Melanoma Detection; Company to Host Conference Call at 8:30 a.m. EST Friday

Electro-Optical Sciences, Inc. ("EOS") (NasdaqCM:MELA ) today announced positive top-line results of its pivotal trial of MelaFind, a non-invasive, point-of-care instrument to assist in the early detection of melanoma, the deadliest form of skin cancer. The blinded study, conducted at seven centers across the US, included 1,831 pigmented skin lesions from 1,383 patients, making this the largest prospective study ever conducted in melanoma detection. EOS is working to complete its Pre-Market Approval (PMA) application and expects to file it with the US Food and Drug Administration (FDA) shortly.

Published: 13 February 2009
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News  
Read more: Electro-Optical Sciences Inc ( MELA )

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2008

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2008.

For the fourth quarter of 2008, Illumina reported revenue of $160.9 million, a 43% increase over the $112.6 million reported in the fourth quarter of 2007 and a 7% increase over revenue of $150.3 million in the third quarter of 2008. This represents the Company's 30th consecutive quarter of revenue growth. The Company reported GAAP net income for the quarter of $28.9 million, or $0.22 per diluted share, compared to a GAAP net loss of $4.1 million, or ($0.04) per basic and diluted share in the comparable period of 2007.

Published: 04 February 2009
Written by Editor
Nasdaq   Healthcare   Financial Results   Up on News  
Read more: Illumina Inc ( ILMN )

Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Neurosurgery, the official journal of the Congress of Neurological Surgeons, has issued a peer-reviewed supplement dedicated to CyberKnife radiosurgery experience.

The supplement, titled "CyberKnife Stereotactic Robotic Radiosurgery" features 15 papers from seven different countries, focused on brain and spine treatment using the CyberKnife(R) Robotic Radiosurgery System. All papers were subjected to thorough peer review by the editorial board of Neurosurgery and describe a wide range of CyberKnife treatment experiences. These papers highlight experience with the CyberKnife System from studies as large as 1,075 patients and for follow-up periods up to five years or more.

Published: 30 January 2009
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News  
Read more: Accuray Incorporated ( ARAY )

American Medical Systems Announces FDA Clearance for Elevate Anterior and Apical Prolapse Repair System

American Medical Systems, Inc., (AMS) (NASDAQ: AMMD) today announced FDA clearance of its Elevate Anterior Prolapse Repair System. This latest addition to the AMS product line, along with the successful launch of Elevate Posterior Prolapse Repair System in 2008, provides a comprehensive solution for treating all types of prolapse. The condition affects more than 30 million women in the United States and is caused when one or more female pelvic organs protrude or herniate into the vaginal wall, which often causes pain, discomfort and other symptoms.

Designed with safety in mind, Elevate Anterior Prolapse Repair System is a minimally invasive, single-incision total transvaginal approach for treating cystoceles and vault prolapse. It utilizes minimal blind needle passages and follows proven implant pathways.

Published: 09 January 2009
Written by Editor
Nasdaq   Healthcare   FDA HC Decision   Up on News  
Read more: American Medical Systems Inc ( AMMD )

Urodynamix Technologies Ltd. Receives FDA 510(k) Clearance for UroNIRS 2000(TM) Bladder Monitor System

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that it has obtained 510(k) clearance from the U.S. Food and Drug Administration to market the UroNIRS 2000(TM) Bladder Monitor System - a second generation non-invasive medical device that uses near infrared spectroscopy (NIRS) to aid in the diagnosis of lower urinary tract symptoms (LUTS) in a urology office setting.

UroNIRS 2000(TM) is a standalone device that does not require conventional external or peripheral urodynamics equipment for its operation, unlike first generation UroNIRS technology. This will allow Urodynamix to expand distribution of its UroNIRS products into urology office markets targeting the 20 million men in the U.S. with symptoms of benign prostatic hyperplasia (BPH) many of whom require diagnosis prior to effective treatment.

Published: 05 January 2009
Written by Editor
TSX Venture   Healthcare   FDA HC Decision   Up on News  
Read more: Urodynamix Technologies Ltd ( URO )
  1. ArthroCare Corp ( ARTC )
  2. Thoratec Corporation ( THOR )
  3. Orthofix International NV ( OFIX )
  4. Pyng Medical Corp ( PYT )
  5. Mentor Corporation ( MNT )